Iron indices: What do they really mean?

Kidney International

Volumn 69, Issue SUPPL. 101, 2006, Pages S4-

  Coyne, D ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anemia; i.v. iron; Inflammation malnutrition; Iron deficiency; Iron markers; Serum ferritin

Indexed keywords

FERRITIN; IRON; RECOMBINANT ERYTHROPOIETIN; TRANSFERRIN;

FERRITIN BLOOD LEVEL; HEMODIALYSIS; HUMAN; INFLAMMATION; IRON BALANCE; IRON BINDING CAPACITY; IRON DEFICIENCY ANEMIA; IRON STORAGE; IRON THERAPY; KIDNEY FAILURE; MALNUTRITION; MORTALITY; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TRANSFERRIN BLOOD LEVEL;

EID: 33749867832     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5000404     Document Type: Article

References (29)

1. National Kidney Foundation. K/DOQI clinical practice guidelines for anemia of chronic kidney disease. Am J Kidney Dis 2001; 37(Suppl 1): S182-S238.
2. Cannella G, La Canna G, Sandrini M et al. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemic dialysed uraemic patients. Nephrol Dial Transplant 1991; 6: 31-37.
3. Carletti P, Bibiano L, Boggi R et al. Does anemia correction by rHuEPO improve uremic cardiopathy? Kidney Int 1993; 43(Suppl 41): S70-S71.
4. Eschbach JW, Egrie JC, Downing MR et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-78.
5. Powe NR, Griffiths RI, Watson AJ et al. Effect of recombinant erythropoietin on hospital admissions, readmissions, length of stay, and costs of dialysis patients. J Am Soc Nephrol 1994; 4: 1455-1465.
6. Harnett JD, Kent GM, Foley RN, Parfrey PS. Cardiac function and hematocrit level. Am J Kidney Dis 1995; 25(Suppl 1): S3-S7.
7. Sakiewicz P, Paganini E. The use of iron in patients on chronic dialysis: mistakes and misconceptions. J Nephrol 1998; 11: 5-15.
8. Cook JD, Eschbach JW. Iron absorption and loss in chronic renal disease. In: Kief H (ed). Iron Metabolism and Its Disorders. Excerpta Medica International Congress Series No. 366. Excerpta Medica: Amsterdam, Netherlands, 1975, pp 190-198.
9. Eschbach JW, Adamson JW. Iron overload in renal failure patients: changes since the introduction of erythropoietin therapy. Kidney Int 1999; 55(Suppl 69): S35-S43.
10. Sunder-Plassmann G, Hörl WH. Importance of iron supply for erythropoietin therapy. Nephrol Dial Transplant 1995; 10: 2070-2076.
11. U.S. Renal Data System. USRDS 1995 Annual Data Report. Atlas of End-Stage Renal Disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. Division of Kidney, Urologic and Hematologic Diseases: Bethesda, MD.
12. Eschbach JW. Iron requirements in erythropoietin therapy. Best Pract Res Clin Haematol 2005; 18: 347-361.
13. Guyatt GH, Oxman AD, Ali M et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med 1992; 7: 145-153.
14. Kalantar-Zadeh K, Rodriguez RA, Humphreys MH. Association between serum ferritin and measures of inflammation, nutrition and iron in haemodialysis patients. Nephrol Dial Transplant 2004; 19: 141-149.
15. Weiss G, Goodnough LT. Anemia of chronic disease. N Engl J Med 2005; 352: 1011-1023.
16. Fleming RE, Sly WS. Hepcidin: a putative iron-regulatory hormone relevant to hereditary hemochromatosis and the anemia of chronic disease. Proc Natl Acad Sci USA 2001; 98: 8160-8162.
17. Kalantar-Zadeh K, Ikizler A, Block G et al. Malnutrition-inflammation complex syndrome in dialysis patients: causes and consequences. Am J Kidney Dis 2003; 42: 864-881.
18. Kalantar-Zadeh K, Regidor DL, McAllister CJ et al. Time-dependent associations between iron and mortality in hemodialysis patients. J Am Soc Nephrol 2005; 16: 3070-3080.
19. Jacobs C, Frei D, Perkins AC. Results of the European Survey on Anaemia Management 2003 (ESAM 2003): current status of anaemia management in dialysis patients, factors affecting epoetin dosage and changes in anaemia management over the last 5 years. Nephrol Dial Transplant 2005; 20(Suppl 3): iii3-iii24.
20. Ikizler TA. Epidemiology of vascular disease in renal failure. Blood Purif 2002; 20: 6-10.
21. Feldman HI, Joffe M, Robinson B et al. Administration of parenteral iron and mortality among hemodialysis patients. J Am Soc Nephrol 2004; 15: 1623-1632.
22. Fishbane S, Shapiro W, Dutka P et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int 2001; 60: 2406-2411.
23. Tessitore N, Solero GP, Lippi G et al. The role of iron status markers in predicting response to intravenous iron in haemodialysis patients on maintenance erythropoietin. Nephrol Dial Transplant 2001; 16: 1416-1423.
24. Beutler E, Hoffbrand AV, Cook JD. Iron deficiency and overload. Hematology (Am Soc Hematol Educ Program) 2003: 40-61.
25. Bacon BR, Olynyk JK, Brunt EM et al. HFE genotype in patients with hemochromatosis and other liver diseases. Ann Intern Med 1999; 130: 953-962.
26. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974; 290: 1213-1216.
27. Morrison ED, Brandhagen DJ, Phatak PD et al. Serum ferritin level predicts advanced hepatic fibrosis among U.S. patients with phenotypic hemochromatosis. Ann Intern Med 2003; 138: 627-633.
28. Guyader D, Jacquelinet C, Moirand R et al. Noninvasive prediction of fibrosis in C282Y homozygous hemochromatosis. Gastroenterology 1998; 115: 929-936.
29. Chang C-H, Chang C-C, Chiang S-S. Reduction in erythropoietin doses by the use of chronic intravenous iron supplementation in iron-replete hemodialysis patients. Clin Nephrol 2002; 57: 136-141.